[144] Guardant Health, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Guardant Health, Inc. (GH) shows a planned sale of 26 shares of common stock to be executed on 08/19/2025 through Charles Schwab & Co., with an aggregate market value of $1,534.52. The filing reports the 26 shares were acquired on 08/15/2025 in a restricted stock lapse from Guardant Health as equity compensation. The issuer's outstanding shares are listed as 124,705,857. The notice also discloses three sales by the same person in the past three months: 2,626 shares on 06/16/2025 for $130,512.00, 26 shares on 06/18/2025 for $1,286.00, and 26 shares on 07/17/2025 for $1,253.00. The filer affirms no undisclosed material nonpublic information.

Positive

• Transparent compliance: The filer discloses acquisition date, nature of acquisition, broker, and recent sales history as required by Rule 144.
• Small planned sale relative to shares outstanding: 26 shares (aggregate $1,534.52) is immaterial versus 124,705,857 outstanding shares.

Negative

• Recent insider selling activity: The filer sold 2,626 shares on 06/16/2025 for $130,512.00, which may prompt investor questions despite limited scale.
• Limited contextual information: Filing does not include plan-adoption date or signature details, reducing clarity about Rule 10b5-1 reliance.

Insights

Securities Analyst

TL;DR: Small planned sale from an equity-compensation lapse; prior insider sales occurred but amounts appear immaterial to market cap.

The filing documents a routine Rule 144 notice for 26 shares derived from a restricted stock lapse and identified as equity compensation. The planned sale's aggregate value of $1,534.52 is trivial versus the stated 124.7 million shares outstanding, suggesting negligible direct impact on share supply or valuation. Historical sales in mid-June and July include a larger 2,626-share sale generating $130,512, which is still small relative to company scale. No financial performance data or new material disclosures are present, so this is a compliance filing rather than a business signal.

Corporate Governance Expert

TL;DR: Filing reflects disclosure compliance for insider sales; confirms representation of no undisclosed material information.

The document meets Rule 144 disclosure requirements by recording acquisition details, sale intent, broker, and recent sales history for the same account. Reporting that the 26 shares arose from a restricted stock lapse and were acquired on 08/15/2025 provides clarity about insider compensation realization. The signer’s attestation that they possess no undisclosed material information is standard and necessary for compliance. No governance events, executive changes, or plan-adoption dates are provided in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	26	1534.52	124705857	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Lapse	Guardant Health, Inc.			26	08/15/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MYRTLE S POTTER 3100 HANOVER STREET PALO ALTO CA 94303	Guardant Health, Inc.	06/16/2025	2626	130512.00
MYRTLE S POTTER 3100 HANOVER STREET PALO ALTO CA 94303	Guardant Health, Inc.	06/18/2025	26	1286.00
MYRTLE S POTTER 3100 HANOVER STREET PALO ALTO CA 94303	Guardant Health, Inc.	07/17/2025	26	1253.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Guardant Health (GH) disclose?

It discloses a proposed sale of 26 common shares to occur on 08/19/2025 via Charles Schwab, with aggregate market value $1,534.52.

How were the 26 shares acquired according to the filing?

The 26 shares were acquired on 08/15/2025 through a restricted stock lapse from Guardant Health and noted as equity compensation.

Does the filing report recent sales by the same person?

Yes. It reports sales of 2,626 shares on 06/16/2025 for $130,512.00, 26 shares on 06/18/2025 for $1,286.00, and 26 shares on 07/17/2025 for $1,253.00.

Who is the broker named for the planned sale?

The broker listed is Charles Schwab & Co., Inc., 3000 Schwab Way, Westlake TX 76262.

How many shares outstanding does the filing list for Guardant Health?

The filing lists 124,705,857 shares outstanding.